1. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) 
Alfredo Carrato, Albert Abad, Bartomeu Massuti, Cristina Grávalos, Pilar Escudero, Federico Longo-Muñoz, José-Luis Manzano, Auxiliadora Gómez, María José Safont, Javier Gallego, Beatriz García-Paredes, Carles Pericay, Rosario Dueñas, Fernando Rivera, Ferrán Losa, Manuel Valladares-Ayerbes, Encarnación González, Enrique Aranda 
European Journal of Cancer 
Volume 81, Pages (August 2017)
DOI: /j.ejca
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1
Study flow-chart.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Progression-free survival (top) and overall survival (bottom) in the WT-KRAS population and in the WT-RAS population.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Overall survival according to early tumour shrinkage ≥30% or <30% at week 8 (left) and according to surgical resection of liver metastases (right) in the WT-RAS population.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2017 The Authors Terms and Conditions